206 related articles for article (PubMed ID: 25319043)
1. Cognitive and psychological functioning in Fabry disease.
Sigmundsdottir L; Tchan MC; Knopman AA; Menzies GC; Batchelor J; Sillence DO
Arch Clin Neuropsychol; 2014 Nov; 29(7):642-50. PubMed ID: 25319043
[TBL] [Abstract][Full Text] [Related]
2. Cognitive dysfunction and depression in Fabry disease: a systematic review.
Bolsover FE; Murphy E; Cipolotti L; Werring DJ; Lachmann RH
J Inherit Metab Dis; 2014 Mar; 37(2):177-87. PubMed ID: 23949010
[TBL] [Abstract][Full Text] [Related]
3. The neurocognitive impact of Fabry disease on pediatric patients.
Bugescu N; Alioto A; Segal S; Cordova M; Packman W
Am J Med Genet B Neuropsychiatr Genet; 2015 Apr; 168B(3):204-10. PubMed ID: 25739920
[TBL] [Abstract][Full Text] [Related]
4. White matter integrity correlates with cognition and disease severity in Fabry disease.
Ulivi L; Kanber B; Prados F; Davagnanam I; Merwick A; Chan E; Williams F; Hughes D; Murphy E; Lachmann RH; Wheeler-Kingshott CAMG; Cipolotti L; Werring DJ
Brain; 2020 Dec; 143(11):3331-3342. PubMed ID: 33141169
[TBL] [Abstract][Full Text] [Related]
5. Cognitive testing in Fabry disease: pilot using a brief computerized assessment tool.
Elstein D; Doniger GM; Altarescu G
Isr Med Assoc J; 2012 Oct; 14(10):624-8. PubMed ID: 23193784
[TBL] [Abstract][Full Text] [Related]
6. Psychiatric and cognitive profile in Anderson-Fabry patients: a preliminary study.
Segal P; Kohn Y; Pollak Y; Altarescu G; Galili-Weisstub E; Raas-Rothschild A
J Inherit Metab Dis; 2010 Aug; 33(4):429-36. PubMed ID: 20549363
[TBL] [Abstract][Full Text] [Related]
7. A long-term neuropsychological evaluation in Fabry disease.
Loret G; Miatton M; Vingerhoets G; Poppe B; Hemelsoet D
Acta Neurol Belg; 2021 Feb; 121(1):191-197. PubMed ID: 32915382
[TBL] [Abstract][Full Text] [Related]
8. Cognitive dysfunction and white matter hyperintensities in Fabry disease.
Murphy P; Williams F; Davagnanam I; Chan E; Murphy E; Hughes D; Quattrocchi G; Werring DJ; Lachman RH; Cipolotti L
J Inherit Metab Dis; 2022 Jul; 45(4):782-795. PubMed ID: 34994980
[TBL] [Abstract][Full Text] [Related]
9. Social-adaptive and psychological functioning of patients affected by Fabry disease.
Laney DA; Gruskin DJ; Fernhoff PM; Cubells JF; Ousley OY; Hipp H; Mehta AJ
J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S73-81. PubMed ID: 20087663
[TBL] [Abstract][Full Text] [Related]
10. Cognitive functioning and depressive symptoms in Fabry disease: A follow-up study.
Körver S; Geurtsen GJ; Hollak CEM; van Schaik IN; Longo MGF; Lima MR; Dijkgraaf MGW; Langeveld M
J Inherit Metab Dis; 2020 Sep; 43(5):1070-1081. PubMed ID: 32510623
[TBL] [Abstract][Full Text] [Related]
11. Intact cognitive inhibition in patients with fibromyalgia but evidence of declined processing speed.
Veldhuijzen DS; Sondaal SF; Oosterman JM
J Pain; 2012 May; 13(5):507-15. PubMed ID: 22564673
[TBL] [Abstract][Full Text] [Related]
12. Neurological complications of Anderson-Fabry disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Arnao V; Licata G; Pinto A
Curr Pharm Des; 2013; 19(33):6014-30. PubMed ID: 23448452
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.
Hopkin RJ; Cabrera G; Charrow J; Lemay R; Martins AM; Mauer M; Ortiz A; Patel MR; Sims K; Waldek S; Warnock DG; Wilcox WR
Mol Genet Metab; 2016 Sep; 119(1-2):151-9. PubMed ID: 27510433
[TBL] [Abstract][Full Text] [Related]
14. Predictors of objective cognitive impairment and subjective cognitive complaints in patients with Fabry disease.
Körver S; Geurtsen GJ; Hollak CEM; van Schaik IN; Longo MGF; Lima MR; Vedolin L; Dijkgraaf MGW; Langeveld M
Sci Rep; 2019 Jan; 9(1):188. PubMed ID: 30655570
[TBL] [Abstract][Full Text] [Related]
15. Anderson-Fabry disease: a multiorgan disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
[TBL] [Abstract][Full Text] [Related]
16. Cognitive impairment differs between primary progressive and relapsing-remitting MS.
Ruet A; Deloire M; Charré-Morin J; Hamel D; Brochet B
Neurology; 2013 Apr; 80(16):1501-8. PubMed ID: 23516324
[TBL] [Abstract][Full Text] [Related]
17. Fabry disease and the skin: data from FOS, the Fabry outcome survey.
Orteu CH; Jansen T; Lidove O; Jaussaud R; Hughes DA; Pintos-Morell G; Ramaswami U; Parini R; Sunder-Plassman G; Beck M; Mehta AB;
Br J Dermatol; 2007 Aug; 157(2):331-7. PubMed ID: 17573884
[TBL] [Abstract][Full Text] [Related]
18. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry.
Sims K; Politei J; Banikazemi M; Lee P
Stroke; 2009 Mar; 40(3):788-94. PubMed ID: 19150871
[TBL] [Abstract][Full Text] [Related]
19. The impact of oculomotor functioning on neuropsychological performance in Huntington disease.
Carvalho JO; Long JD; Westervelt HJ; Smith MM; Bruce JM; Kim JI; Mills JA; Paulsen JS;
J Clin Exp Neuropsychol; 2016; 38(2):217-26. PubMed ID: 26745770
[TBL] [Abstract][Full Text] [Related]
20. Association between psychological distress, subjective cognitive complaints and objective neuropsychological functioning in brain tumor patients.
Pranckeviciene A; Deltuva VP; Tamasauskas A; Bunevicius A
Clin Neurol Neurosurg; 2017 Dec; 163():18-23. PubMed ID: 29035741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
